Acorda Therapeutics reports Ampyra ER tablets net sales of $166M for Q4
Acorda Therapeutics reported AMPYRA Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166M. Unaudited 2017 full-year net sales were $542M, an increase of approximately 10% from 2016. Final results are subject to completion of the company's year-end audit. "In response to the challenges we faced in 2017, we streamlined Acorda to focus on our most important and valuable initiatives. Based on the Company's proven track record of commercial success in the specialty neurology space, an NDA submitted for a major product and a continued commitment to fiscal responsibility, 2018 will be a transformative year for Acorda," said Ron Cohen, M.D., Acorda's President and CEO. "We are preparing for potential approval and launch of INBRIJA, our investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. We look forward to working with the FDA during the NDA review process, and to bringing this new treatment option to the PD community to help address an important unmet need. Based on our continued market research we have increased our projection for INBRIJA's US market opportunity to greater than $800M. We are well capitalized through the launch of INBRIJA, and are projecting a 2018 year-end cash balance of over $300M. We are also continuing to prosecute the AMPYRA appeal vigorously in the appellate court. Depending on the outcome of that appeal, we expect to maintain exclusivity of AMPYRA at least through July 2018."